Drug Manufacturers - General

Biogen Inc.

BIIB·NasdaqGS·Website

Latest price

—

Opened at: —
Today's high: —
Today's low: —
Company size: $28.15B

How the price has moved

Loading…

What you need to know

We're putting together a quick summary…

Looking up the company

About Biogen Inc.

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Source: company filings via Yahoo Finance. Educational only — not investment advice.

Recent news about BIIB

What people are saying about the company

The basics

Quick reads on growth, price, and stability

Share price

—

How much the share price has gained over the last year. The 5-year average is the typical yearly return over the past 5 years.

Will it grow?

The signs that the business is getting bigger and more profitable

Sales growth
—
How much the company's total sales went up (or down) over the last year. We show the 5-year average alongside so you can see if growth is steady, speeding up, or slowing down.
Profit growth
—
How much the company's profit per share went up over the last year, with the 5-year average shown next to it. Profit growing faster than sales usually means the business is getting more efficient.
Profit margin
—
Out of every $100 of sales, how much the company keeps as profit. Higher means they have pricing power and aren't getting squeezed by costs.
How well they use the money
—
A different question from 'is it expensive?'. P/E asks how much YOU pay for the stock. This one asks how good the COMPANY is at turning shareholder money into profit. 15% means they squeeze $15 of profit a year out of every $100 of shareholder money sitting in the business.

Is the price fair?

Whether you're paying a reasonable amount for what you get

Is it expensive?
—
How many dollars investors pay for $1 of yearly profit. 20× means $20 today for $1 of profit a year. Lower is usually cheaper. Compare to growth — fast growers can earn higher P/E.
Year's range
—
The lowest and highest the share has traded over the past year. If today's price is near the high, the stock is priced for optimism; near the low, sentiment is gloomier.

Is it healthy?

How stable the company is — and whether shareholders get cash back

Debt vs ownership
—
How much the company owes (debt) compared to what the shareholders own (equity). Above 1.0 means more borrowed than owned — high debt makes a company more fragile when times get tough.
Cash back to investors
—
If the company pays cash to shareholders, how much per year as a % of price. 3% means $3/year for every $100 invested. Many growth companies pay nothing and reinvest instead.

How big is it?

Company size
—
What the whole company is worth — share price times every share. The headline 'price tag' of the business.

How they've been doing

Last four quarters · expected vs. actual earnings

Similar companies

Other stocks in the same neighbourhood